Nowadays, orthotopic liver transplantation is considered the most efficient approach to the end stage of chronic hepatic cirrhosis. Because of the limitations of orthotopic liver transplantation, stem cells are an attractive therapeutic option. Mesenchymal stem cells (MSCs) especially show promise as an alternative treatment for hepatic cirrhosis in animal models and during clinical trials. Nevertheless, the homing of transplanted MSCs to the liver occurs in limited numbers. Therefore, we review the strategies for enhancing the homing of MSCs, mainly via the delivery routes, optimizing cell culture conditions, stimulating the target sites, and genetic modification.
CITATION STYLE
Zhang, Y., Li, Y., Zhang, L., Li, J., & Zhu, C. (2018, March 9). Mesenchymal stem cells: Potential application for the treatment of hepatic cirrhosis. Stem Cell Research and Therapy. BioMed Central Ltd. https://doi.org/10.1186/s13287-018-0814-4
Mendeley helps you to discover research relevant for your work.